Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The demise of the corpus luteum is brought about by an interaction between ovarian
oxytocin
and uterine prostaglandin F2 alpha (PGF2 alpha) release in sheep. Indirect evidence suggests that a similar, but intra-ovarian, mechanism may also be involved in luteal regression in primates. During early pregnancy, a specific class of interferon (omega interferon) is released from the developing embryo in sheep and this interferon inhibits pulsatile release of uterine PGF2 alpha. Studies in ovariectomized, steroid-treated ewes indicate that conceptus secretory proteins inhibit pulsatile secretion of PGF2 alpha directly via an effect on prostaglandin synthesis and indirectly by maintaining plasma progesterone concentrations that inhibit the development of endometrial
oxytocin
receptors which normally occurs at the time of luteolysis. As pregnancy progresses, there is an increase in basal secretion of PGF2 alpha and PGE2 from the uterus into the fetal and maternal circulation. The release of maternal PGF2 alpha, but not PGE2, in response to
oxytocin
is also increased in late pregnancy. Endometrial oxytocin receptor concentrations follow a similar pattern, except at parturition where there appears to be downregulation of receptors. However, the release of PGF2 alpha in response to
oxytocin
remains high at this time and is further increased if the progesterone receptors are blocked with the anti-progestin RU486. The dissociation between oxytocin receptor numbers and release of prostaglandins in response to
oxytocin
is also observed under other physiological situations, such as during seasonal anoestrus and after long-term ovariectomy, and requires further investigation. The role of
oxytocin
in the initiation of labour remains controversial. Although
oxytocin
concentrations in maternal and fetal plasma are not increased until parturition, uterine oxytocin receptor concentrations, uterine activity and maternal PGF2 alpha release in response to
oxytocin
are high in late pregnancy. Uterine activity and PG release is not altered by
oxytocin
in the fetal circulation at any stage of late gestation. We have used the
oxytocin
analogue
CAP
to investigate further the possible role of
oxytocin
in the initiation of labour.
CAP
can inhibit
oxytocin
-induced PGF2 alpha release in cyclic sheep, at luteolysis, and in late pregnant sheep by binding to, and blocking, uterine
oxytocin
receptors.
CAP
does not inhibit basal fetal or maternal PGF2 alpha or PGE2 concentrations in late pregnancy or at parturition.
CAP
inhibits
oxytocin
-induced uterine activity and delays, but does not prevent, the increase in uterine activity associated with labour in this species.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Oxytocin and prostaglandin interactions in pregnancy and at parturition. 130 35
The pulsatile release of
oxytocin
from the corpus luteum in the sheep is responsible for the pulsatile release of prostaglandin F2 alpha (PGF2 alpha) from the uterus at luteolysis. It has been proposed that PGF2 alpha also reinforces this process by stimulating the release of
oxytocin
from the corpus luteum. It is, however, unlikely that PGF2 alpha is the major stimulus for
oxytocin
release at this time. Although the stimulus for the pulsatile release of
oxytocin
from the corpus luteum appears to reach the ovary from the peripheral circulation, the nature of the stimulus is unknown. Pulses of
oxytocin
originating from the corpus luteum have also been observed during early pregnancy, but the release of PGF2 alpha, in response to this signal, is abrogated in some way by ovine trophoblast protein-1 (oTP-1). This protein has been shown to inhibit endometrial prostaglandin production and to decrease the amount of PGF2 alpha released in response to
oxytocin
. Reduction of uterine oxytocin receptor concentrations by conceptus secretory proteins or by interferons related to oTP-1 remains equivocal. Inhibition of uterine
oxytocin
receptors is, however, probably the major mechanism that prevents luteal regression during early pregnancy. In cyclic sheep the specific inhibition of uterine
oxytocin
receptors by 1-deamino-2-D-Try (oET)-4-Thr-8-Orn-
oxytocin
(
CAP
), a synthetic oxytocin receptor antagonist, inhibits luteal regression and suppresses pulsatile, but not basal, secretion of uterine PGF2 alpha. Thus, the effects of
CAP
directly parallel the endocrinological changes that occur in early pregnancy in the sheep.
...
PMID:Interaction between oxytocin and prostaglandin F2 alpha during luteal regression and early pregnancy in sheep. 133 37
The binding of 3H-
oxytocin
(3H-OT) and 3H-arginine-vasopressin (3H-AVP) and the displacement from binding sites by four
oxytocin
analogues were studied in myometrial membrane preparations from full-term pregnant women. Specific 3H-OT binding was saturable with a maximal binding capacity of 76.1 fmol/mg DNA, and a dissociation constant of 0.5 pM. Corresponding values regarding 3H-AVP was 148.6 fmol/mg DNA and 0.7 pM. The
oxytocin
analogues tested demonstrated a high specific binding to the OT and AVP receptor sites; in fact, the affinity of the analogues to the 3H-AVP binding sites was higher than to the 3H-OT binding sites. The order of potency between the analogues was CAU greater than
CAM
greater than
CAP
greater than CAO and
CAP
greater than CAU greater than CAO greater than
CAM
for the OT and AVP binding sites, respectively. The displacement of
oxytocin
and arginine-vasopressin, respectively, from the myometrial receptor sites indicate partly separate binding sites for
oxytocin
and AVP and might implicate that AVP can be of importance in regulating myometrial activity in pregnancy. The results on
oxytocin
analogues imply that other pharmacological tests must be performed for quantification of the relaxing effects on the uterus and to determine the optimal analogue for clinical trials in preterm labor and dysmenorrhoea.
...
PMID:Binding of four oxytocin analogues to myometrial oxytocin and arginine-vasopressin binding sites in pregnant women. 216 84
Ten different maternal serum samples were analyzed for the hydrolysis of S-Bz-Cys-pNA (substrate for
CAP
) and Ala-pNA. The results showed clear differences in the activities in individual sera. Similar S-Bz-Cys-pNA hydrolysis activity was detected for all sera. However, Ala-pNA hydrolysis activity differed remarkably. Serum exhibiting low Ala-pNA hydrolysis activity contained only
CAP
, and that exhibiting high Ala-pNA hydrolyzing activity contained
CAP
and AAP. The two aminopeptidases were independently purified to a homogeneous state through the same purification procedures and some of their biochemical properties were compared. The enzymes were quite different with respect to molecular mass, the substrate specificities for some aminoacyl-pNA substrates, and the effects of inhibitors. Among various natural peptides tested for hydrolysis, the enzymes hydrolyzed Met-enkephalin most rapidly, but their modes of action were different. Furthermore, only
CAP
degraded
oxytocin
and AAP exhibited a high kinin-converting activity.
...
PMID:Aminopeptidases in human retroplacental sera: purification and characterization of two enzymes. 271 59
The oxytocin receptor inhibitor 1-deamino-2-D-Tyr-(oET)-4-Thr-8-orn-
oxytocin
(
CAP
) was infused into late pregnant sheep. Basal and
oxytocin
-induced prostaglandin (PG) concentrations in maternal and fetal plasma were determined.
CAP
had no significant effect on maternal PGFM or PGE2 or fetal PGF2 alpha, PGFM or PGE2 concentrations during late pregnancy or at term. PGF2 alpha was not detectable in maternal peripheral plasma.
CAP
infusion did not affect fetal well-being.
Oxytocin
injection to the mother caused a significant, dose-dependent, increase in maternal plasma PGFM concentrations but did not alter maternal PGE2 concentrations or fetal PGF2 alpha and PGE2 concentrations. The increase in maternal PGFM concentrations brought about by oxytocin injection was decreased during intrauterine infusion of
CAP
over the range of 12.5-100 micrograms/min. A rationale for the use of oxytocin receptor blockade for the prevention of premature labor is thus provided.
...
PMID:Oxytocin receptor blockade and prostaglandin release in late pregnant sheep. 818 13
Acute unilateral nephrectomy (AUN) in anesthetized male Lewis x DA rats induced rapid and consistent increases in electrolyte and fluid excretion by the remaining kidney during the first hours. Continuous infusion of a vasopressin (AVP) V1-receptor antagonist d(CH2)5Tyr(Me)AVP (V1-ant) reduced renal electrolyte and fluid excretion before and after AUN to a similar extent, whereas an
oxytocin
(OT)-receptor antagonist [Mpa1,D-Tyr(Et)2,Thr4,Orn8]-OT (
CAP
) at the same dose selectively attenuated the increase in sodium excretion after AUN. The plasma concentration of OT rose significantly after AUN (9.16 +/- 1.4 to 21.45 +/- 5.07 pg.ml-1). A similar OT level obtained by infusion of OT mimicked the renal responses to AUN without elevating blood pressure; however, only
CAP
but not V1-ant efficiently reversed OT-induced natriuresis. Also, the infusion of
CAP
at the same dose produced no effects on the rise of blood pressure caused by AVP while the infusion of the V1-ant prevented such a rise. Thus,
CAP
reduced the natriuresis after AUN by interfering with OT- and not V1-receptors. In conclusion, evidence is presented, for the first time, concerning the major role of OT receptors in the acute readjustment of the renal sodium excretion after AUN, and a synergistic role for AVP in terms of the general magnitude of renal excretion.
...
PMID:Effects of neurohypophyseal antagonists in postnephrectomy natriuresis in male rats. 819 72
Two different forms of oxytocinase (L-cystine aminopeptidase,
CAP
; EC 3.4.11.3) were purified from the 9000 g and 105000 g precipitate fractions of human placenta homogenate by sequential chromatography on columns of hydroxyapatite, DE-32, nickel ion affinity, and Sephadex G-200. One species (
CAP
-I) purifed from the mitochondrial/lysosomal fraction migrated on sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis with an apparent molecular mass of 61 kDa; the other (
CAP
-II) from the microsomal fraction was composed of two subunits with molecular masses of 56 and 40 kDa. The molecular masses of
CAP
-I and
CAP
-II estimated by gel filtration were 64 and 97 kDa, respectively. The specific activities of the two species for S-benzyl-L-cysteine p-nitroanilide increased by 357- (for
CAP
-I) and 139-fold (for
CAP
-II) compared with the starting preparations. The optimal pH values toward the artificial substrate were approx. 7.4-8.0 for
CAP
-I and 6.8-8.0 for
CAP
-II. The Km and Vmax values toward
oxytocin
were 5.6 microM and 23.4 micromol/h/mg protein for
CAP
-I, and 38 microM and 15.6 micromol/h/mg protein for
CAP
-II. Both enzymes were inhibited by the metal-chelating agents, EDTA and o-phenanthroline, whereas they were specifically activated by addition of Co2+:
CAP
-I was more sensitive to these reagents than
CAP
-II. L-Methionine strongly inhibited
CAP
-I, while
CAP
-II activity was only slightly affected.
CAP
-II was more sensitive to amastatin than
CAP
-I. Thus, the two enzymes are quite distinct in their molecular nature and biochemical properties. They may play a regulatory role in the metabolism of
oxytocin
and other biologically active peptides in intact placenta.
...
PMID:Two molecular species of oxytocinase (L-cystine aminopeptidase) in human placenta: purification and characterization. 901
It was shown that
oxytocin
(OT) elicits electrophysiological responses in cultured monolayers of NCL-SG3, a human immortalized sweat gland cell line. The response to OT was greater for basal applications. It was also found that monolayers respond to ATP with a transient transepithelial-potential change, with a more pronounced response to apical than to basal applications. The IC50 for the response to OT was 180 nM at room temperature. The response to OT was not due to effects of OT on vasopressin (AVP) receptors as evidenced by three tests: (a) The response was completely blocked by the selective OT-receptor antagonist [Mpa1,D-Tyr(Et)2,Thr4,Orn8]-OT (
CAP
) applied at equal concentrations (100-1000 nM) to that of OT. (b) The response to OT was similar to that of ionomycin (2 microM) or ATP (150 microM). In contrast, the response to AVP (500 nM) or cAMP (2 mM) were smaller and of a different time course. (c) OT increased but AVP had no effect on the intracellular free calcium. It is suggested that OT may have a role in the regulation of salt balance in sweating.
...
PMID:Electrophysiological responses to oxytocin and ATP in monolayers of a human sweat gland cell line. 916 54
Subluteolytic doses of prostaglandin F2alpha analogue (oestrophan) given i.m. and
oxytocin
(OT) antagonist (
CAP
) and noradrenaline (NA) infused into the abdominal aorta were used to test the importance of luteal OT in pulsatile secretion of prostaglandin F2alpha (PGF) during luteolysis in heifers (n = 17). In experiment 1, heifers were pre-infused for 30 minutes with saline on either day 17 of the oestrous cycle (group 1; n = 4) or on day 18 of the oestrous cycle (group 2; n = 3), and with
CAP
(8 mg per animal) on day 17 of the oestrous cycle (group 3; n = 4). Next, heifers were injected with oestrophan (30 microg per animal). Injection of oestrophan in Group 3 increased OT concentrations (P < 0.001) to values similar to those observed during spontaneous luteolysis (50 to 70 pg ml(-1)). PGFM concentrations in this group also increased (P < 0.001), but were lower (P < 0.05) than the values in groups 1 and 2,
CAP
given prior to oestrophan decreased both PGFM elevation (P < 0.06) and its area under the curve (P < 0.01), compared to the saline pretreated heifers. In experiment 2 NA (4 mg) was infused twice for 30 minutes at five hour intervals to release OT on day 17 of the oestrous cycle (n = 6). However, during hormone analysis it appeared that three of six heifers had elevated PGFM concentrations (group 1) and three others did not (group 2). NA caused the correlated increase of progesterone and OT secretion (r = 0.68; P < 0.05) in both groups but it only influenced PGF secretion in group 1 only (P < 0.05). We postulate that OT can amplify and modulate the course of induced luteolysis as a regulator of the amplitude of pulsatile PGF secretion. PGF analogue stimulates secretion of endogenous PGF from the uterus in cattle and this may be an important component of the luteolytic response to exogenous PGF.
...
PMID:Oxytocin modulates the pulsatile secretion of prostaglandin F2alpha in initiated luteolysis in cattle. 1008 4
The role of
oxytocin
(OT) in the regulation of prostaglandin F2 alpha (PGF2 alpha) secretion during luteolysis in gilts was studied using a highly specific OT antagonist (
CAP
-581). In Experiment 1 gilts on Days 14 to 19 of the oestrous cycle in Latin square design were used, to determine the dose and time of application of OT and
CAP
. In Group I (n = 6) gilts were treated intravenously with saline or with 10, 20 and 30 IU of OT. Concentrations of the main PGF2 alpha metabolite i.e. 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM) were measured in blood samples as uterine response to the treatment. Twenty IU of OT was the most effective to stimulate PGFM release and this dose was used after
CAP
treatment in gilts of Groups II, III and IV. Gilts of Group II (n = 3) were injected into the uterine horns (UH) with saline (5 ml/horn) or
CAP
(2 mg, 3 mg and 4 mg; half dose/horn) and OT was injected (i.v.) 30 min thereafter. Any of the
CAP
doses given into the UH affected PGFM plasma concentrations stimulated by OT. In Group III (n = 4) gilts were infused (i.v.) for 30 min with
CAP
(9 mg, 14 mg and 18 mg/gilt) followed by 20 IU of OT. All doses of
CAP
effectively inhibited OT-stimulated PGF2 alpha release, therefore 9 mg was selected for the further studies. Gilts of Group IV (n = 4) received OT 4, 6 and 8 h after
CAP
to define how long
CAP
blocks the OT receptors. Concentrations of PGFM increased after any of this period of time. Thus, we concluded that 9 mg of
CAP
infused every 4 h will effectively block OT receptors. In Experiment 2, gilts (n = 4) received
CAP
as a 30-min infusion every 4 h on Days 12-20 of the oestrous cycle. Control gilts (n = 3) were infused with saline.
CAP
infusions diminished the height of PGFM peaks (P < 0.05). Frequency of the PGFM (P < 0.057) and OT (P < 0.082) peaks only tended to be lower in the
CAP
-treated gilts. Peripheral plasma concentrations of progesterone (P4) and oestradiol-17 beta (E2) and the time of luteolysis initiation as measured by the decrease of P4 concentration were the same in
CAP
- and saline-treated gilts. The macroscopic studies of the ovaries in gilts revealed lack of differences between groups. We conclude that OT is involved in the secretion of luteolytic PGF2 alpha peaks but its role is limited to controlling their height and frequency. Blocking of OT receptors did not prevent luteolysis in sows.
...
PMID:Effect of an oxytocin antagonist on prostaglandin F2 alpha secretion and the course of luteolysis in sows. 1034 85
1
2
Next >>